Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery

被引:476
作者
van Vlerken, Lilian E. [1 ]
Vyas, Tushar K. [1 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA
关键词
intracellular delivery; long-circulation; poly(ethylene glycol); polymeric nanocarriers; tumor targeting;
D O I
10.1007/s11095-007-9284-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The success of anti-cancer therapies largely depends on the ability of the therapeutics to reach their designated cellular and intracellular target sites, while minimizing accumulation and action at nonspecific sites. Surface modification of nanoparticulate carriers with poly(ethylene glycol) (PEG)/ poly(ethylene oxide) (PEO) has emerged as a strategy to enhance solubility of hydrophobic drugs, prolong circulation time, minimize non-specific uptake, and allow for specific tumor-targeting through the enhanced permeability and retention effect. Furthermore, PEG/PEO modification has emerged as a platform for incorporation of active targeting ligands, thereby providing the drug and gene carriers with specific tumor-targeting properties through a flexible tether. This review focuses on the recent developments surrounding such PEG/PEO-surface modification of polymeric nanocarriers to promote tumor-targeting capabilities, thereby enhancing efficacy of anti-cancer therapeutic strategies.
引用
收藏
页码:1405 / 1414
页数:10
相关论文
共 82 条
[1]   Amphiphilic block copolymers for drug delivery [J].
Adams, ML ;
Lavasanifar, A ;
Kwon, GS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (07) :1343-1355
[2]  
[Anonymous], 2006, Cancer Facts and Figures
[3]  
Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
[4]   Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery [J].
Bellocq, NC ;
Pun, SH ;
Jensen, GS ;
Davis, ME .
BIOCONJUGATE CHEMISTRY, 2003, 14 (06) :1122-1132
[5]   Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice [J].
Bibby, DC ;
Talmadge, JE ;
Dalal, MK ;
Kurz, SG ;
Chytil, KM ;
Barry, SE ;
Shand, DG ;
Steiert, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 293 (1-2) :281-290
[6]   Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model [J].
Brigger, I ;
Morizet, J ;
Laudani, L ;
Aubert, G ;
Appel, M ;
Velasco, V ;
Terrier-Lacombe, MJ ;
Desmaële, D ;
d'Angelo, J ;
Couvreur, P ;
Vassal, G .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :29-40
[7]   Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen [J].
Chawla, JS ;
Amiji, MM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 249 (1-2) :127-138
[8]   Targeting proteins to mitochondria using TAT [J].
Del Gaizo, V ;
MacKenzie, JA ;
Payne, RM .
MOLECULAR GENETICS AND METABOLISM, 2003, 80 (1-2) :170-180
[9]   The dawning era of polymer therapeutics [J].
Duncan, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :347-360
[10]   Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies [J].
Elbayoumi, Tamer A. ;
Torchilin, Vladimir P. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (10) :1196-1205